Emeka Eziri, MD
Pulmonary Disease · Gastonia, NCNPI 1649251125
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Boehringer Ingelheim at 39.6% of the total. 2025 is the largest year on record at $18,231, more than ten times the $1,122 reported in 2019. Among pulmonary disease clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 245 payments — averaging $115.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$11K
- Genentech USA, Inc.$5K
- AstraZeneca$4K
- Chiesi USA, Inc.$2K
- ANI Pharmaceuticals, Inc.$2K
- GSK$2K
- plus $2K from 24 others
Across 41 payments — averaging $5673.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$79K
- AstraZeneca$54K
- GSK$48K
- Insmed, Inc.$27K
- Pfizer$12K
- AbbVie$9K
- plus $4K from 2 others
What the payments were for
- Consulting fees$15,12553%
- Speaking & faculty fees$1,7506%
- Travel & lodging$5,20218%
- Food & beverage$6,03921%
- Education$2111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 15 | $11,222 |
| Genentech USA, Inc. | 7 | $4,820 |
| AstraZeneca | 45 | $4,232 |
| Chiesi USA, Inc. | 2 | $2,424 |
| ANI Pharmaceuticals, Inc. | 10 | $1,874 |
| GSK | 94 | $1,546 |
| Grifols USA, LLC | 22 | $292 |
| Jazz Pharmaceuticals Inc. | 5 | $231 |
| Gilead | 2 | $203 |
| Johnson & Johnson | 2 | $188 |
| Paratek Pharmaceuticals, Inc. | 4 | $150 |
| Vertex | 1 | $140 |
| Viiv Healthcare Company | 1 | $125 |
| Novartis | 1 | $121 |
| Amgen | 1 | $117 |
| Regeneron Healthcare Solutions, Inc. | 4 | $111 |
| Mylan Specialty L.p. | 5 | $68 |
| Sanofi | 3 | $57 |
| Electromed, Inc. | 3 | $56 |
| Insmed, Inc. | 3 | $50 |
| Novo Nordisk | 1 | $40 |
| Philips North America LLC | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Harmony Biosciences LLC | 2 | $35 |
| Mallinckrodt Enterprises LLC | 2 | $35 |
| Viatris Specialty LLC | 2 | $34 |
| Shire North American Group Inc | 1 | $25 |
| Vifor Pharma, Inc. | 1 | $24 |
| United Therapeutics Corporation | 1 | $15 |
| Optinose US, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,326 in reported general payments places this provider in the 90th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 326 | $328,621 |
| Breo ElliptaFluticasone/Vilanterol | 145 | $102,242 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 95 | $94,087 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 100 | $73,523 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 46 | $33,131 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 517 | $21,928 |
| Spiriva RespimatTiotropium Bromide | 11 | $16,799 |
| Ventolin HfaAlbuterol Sulfate | 122 | $12,590 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $11,791 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $11,128 |
| Spiriva HandihalerTiotropium Bromide | 20 | $9,984 |
| Fluticasone Propionate | 441 | $9,069 |
| Roflumilast | 142 | $8,655 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $8,008 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $5,144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,546 | $516,177584 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $4,232 | $105,216125 claims |
| Boehringer IngelheimCombivent Respimat, Spiriva Respimat | $11,222 | $49,93057 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Gastonia
- Raed SuleimanGastonia$195K
- Mikell JarrattGastonia$45K
- Anup BanerjeeGastonia$19K
- Jay HendlerGastonia$17K
- Azeem ElahiGastonia$17K
- Michael PritchettPinehurst$1.3M
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- Bradley IcardPinehurst$299K
- James DonohueChapel Hill$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.